Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
NuCana plc NCNA
$0.77
+$0 (0.33%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
41374591.00000000
-
week52high
2.24
-
week52low
0.52
-
Revenue
0
-
P/E TTM
-3
-
Beta
1.25294100
-
EPS
-0.74000000
-
Last Dividend
0.00000000
-
Next Earnings Date
31 мая 2023 г. в 10:59
Описание компании
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Cowen & Co. | Market Perform | Outperform | 03 мар 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 24 ноя 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 01 дек 2020 г. |
| HC Wainwright & Co. | Buy | Buy | 24 ноя 2020 г. |
| Truist Securities | Buy | 22 окт 2020 г. | |
| Jefferies | Buy | Buy | 22 сент 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Why Is NuCana (NCNA) Stock Down 36% Today?
InvestorPlace
27 мар 2023 г. в 09:21
NuCana (NASDAQ: NCNA ) stock is sliding lower on Monday after the company got an unfortunate update from the Technical Board of Appeal (TBA) of the European Patent Office (EPO). The bad news for investors in NCNA stock is the TBA has determined that the company's European Patent 2955190 isn't valid.
NuCana to Participate in Two Upcoming Investor Conferences
GlobeNewsWire
28 февр 2023 г. в 08:00
EDINBURGH, United Kingdom, Feb. 28, 2023 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will participate in two upcoming investor conferences.
NuCana: Pipeline And Major Gilead Litigation Progressing Nicely
Seeking Alpha
08 янв 2023 г. в 04:30
NuCana's market cap is not reflecting the potential of two other drug candidates NUC-3373 and NUC-7738, currently in Phase 2 trials. The UK and EU proceedings against Gilead for alleged years-long infringement of an EU patent have important hearing dates lined up in January and March 2023.
NuCana PLC Sponsored ADR (NCNA) Upgraded to Buy: What Does It Mean for the Stock?
Zacks Investment Research
21 ноя 2022 г. в 13:32
NuCana PLC Sponsored ADR (NCNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why NuCana PLC Sponsored ADR (NCNA) is Poised for a Turnaround After Losing 26.5% in 4 Weeks
Zacks Investment Research
05 окт 2022 г. в 11:18
NuCana PLC Sponsored ADR (NCNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.